Cleaved-F10 (A41) Antibody

What is Cleaved-F10 (A41) Antibody and what specific epitope does it recognize?

Cleaved-F10 (A41) Antibody is a polyclonal antibody that specifically recognizes the cleaved form of Coagulation Factor X at the Ala41 site of the light chain. The antibody was raised against a synthesized peptide derived from the N-terminal region of human Factor X (specifically amino acids 22-71) . This antibody enables detection of the activated form of Factor X, which plays a critical role in the blood coagulation cascade. The specificity for the cleaved form allows researchers to distinguish between inactive and active forms of the protein in experimental settings .

What applications has Cleaved-F10 (A41) Antibody been validated for?

The antibody has been tested and validated primarily for Western Blot (WB) and Enzyme-Linked Immunosorbent Assay (ELISA) applications . The recommended dilution ranges are:

Optimal dilutions should be determined by the end user for each specific experimental setup, as factors such as sample type, detection method, and incubation conditions can affect performance .

What controls should be used to validate specificity in Western Blot applications?

Based on published methodologies, the following controls can verify antibody specificity:

• Peptide competition assay: Pre-incubating the antibody with the synthesized immunogenic peptide should abolish the signal, as demonstrated in Western blot analysis of lysates from A549 cells treated with etoposide (24μM for 24h) .

• Positive control samples: A549 cells have been documented to express detectable levels of the target protein and can serve as positive controls .

• Molecular weight verification: The cleaved light chain should appear at approximately 39 kDa, allowing size-based confirmation of specificity .

How does Cleaved-F10 (A41) Antibody differ from other Factor X antibodies?

Several Factor X antibodies target different cleavage sites or forms of the protein, each providing unique insights into different stages of Factor X processing:

These antibodies allow researchers to study specific cleavage events in the coagulation cascade, providing insight into different activation pathways or disease mechanisms . The choice between these antibodies should be guided by which specific aspect of Factor X processing is being investigated.

What is the mechanism of Factor X cleavage and how does this impact experimental interpretation?

Factor X undergoes proteolytic processing as part of the coagulation cascade. According to established biochemical pathways, Factor X is cleaved by either factor IXa (in the intrinsic pathway) or factor VIIa (in the extrinsic pathway) . The cleavage at Ala41 represents one of the specific processing events during activation.

For experimental interpretation:

• The presence of the cleaved form indicates activation of the coagulation pathway

• Time course experiments can provide insights into activation kinetics

• Comparative studies between normal and pathological samples may reveal differences in Factor X activation

• Treatments affecting proteases involved in Factor X cleavage will likely affect results

How might post-translational modifications affect antibody binding and experimental outcomes?

Factor X undergoes several post-translational modifications that could potentially affect antibody recognition:

• Vitamin K-dependent carboxylation of glutamate residues allows the modified protein to bind calcium

• N- and O-glycosylation (with core 1 or possibly core 8 glycans)

• 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains

If these modifications occur within or near the epitope recognized by the antibody (N-terminal region), they could affect binding affinity or specificity. Researchers should consider how disease states or experimental conditions might alter these modifications and potentially impact antibody recognition.

Can Cleaved-F10 (A41) Antibody be used for investigating coagulation disorders in disease models?

This antibody has significant potential for studying coagulation disorders. Factor X is a key component in the coagulation cascade, converting prothrombin to thrombin in the presence of factor Va, calcium, and phospholipid during blood clotting .

In disease model applications:

• Detection of the cleaved form can indicate aberrant activation of the coagulation system

• Comparative studies between control and disease models may reveal differences in Factor X processing

• When investigating coagulation-related disorders in conditions like cystic fibrosis, researchers should consider how protease inhibitors or other treatments could affect Factor X cleavage and activity

How can this antibody be integrated with functional assays to provide comprehensive insights into Factor X biology?

While the antibody detects the cleaved form of Factor X, combining it with functional assays provides a more comprehensive understanding:

• Combined approach methodology:

  • Use Western blot with Cleaved-F10 (A41) Antibody to assess the presence and relative abundance of the cleaved form

  • Simultaneously perform ELISA-based quantification of total Factor X levels

  • Correlate Factor X cleavage status with coagulation activity measurements

  • Consider using transepithelial current clamp (TECC-24) systems to measure downstream functional effects in appropriate cell models

• Data integration:

  • Correlation between cleaved Factor X levels and functional coagulation parameters

  • Assessment of how experimental interventions affect both Factor X processing and coagulation activity

  • Insights into the relationship between Factor X activation states and disease phenotypes

What are the potential research applications in cardiovascular disease models?

Given Factor X's critical role in coagulation, this antibody has significant applications in cardiovascular research:

• Thrombosis research: Investigating the activation state of Factor X in various thrombotic conditions and assessing how this correlates with clinical manifestations

• Anticoagulant therapy studies: Examining how various anticoagulant interventions affect Factor X cleavage patterns

• Inflammation-coagulation interface: Factor Xa activates pro-inflammatory signaling pathways in a protease-activated receptor (PAR)-dependent manner , allowing investigation of the interplay between inflammation and coagulation

• Atherosclerosis models: Exploring how Factor X activation may contribute to atherosclerotic plaque formation or progression

What is the optimal Western blot protocol for Cleaved-F10 (A41) Antibody?

Based on extensive experimental data, the following protocol optimizations are recommended:

Sample Preparation:

• Include protease inhibitors during extraction to prevent unwanted proteolysis

• For positive controls, consider using A549 cells treated with etoposide (24μM for 24h)

Western Blot Protocol:

• Separate proteins using standard SDS-PAGE

• Transfer to PVDF or nitrocellulose membrane

• Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Incubate with primary antibody at 1:1000 dilution (adjust within range 1:500-1:2000 based on signal strength)

• Wash 3× with TBST

• Incubate with HRP-conjugated anti-rabbit secondary antibody

• Develop using ECL substrate

• Expected molecular weight: approximately 39 kDa for the cleaved light chain

Validation Controls:

• Include peptide competition control by pre-incubating the antibody with the immunizing peptide

Can this antibody be modified for specialized detection methods?

While the antibody is provided unconjugated, it may be possible to modify it for specialized applications:

• Biotin conjugation process:

  • Perform buffer exchange to remove BSA and sodium azide

  • Use a commercial biotinylation kit following manufacturer's instructions

  • Optimize biotin:antibody ratio to maintain binding affinity

  • Store in small aliquots at -20°C

• Fluorophore conjugation:

  • Similar approach to biotinylation, but using appropriate fluorophore conjugation chemistry

  • Verify that conjugation doesn't interfere with epitope binding

  • Validate specificity after modification

• Considerations and limitations:

  • Conjugation may affect binding kinetics or affinity

  • Additional purification steps may be required

  • Specialized validation will be necessary to ensure the modified antibody maintains specificity

What are the recommended storage conditions to maintain antibody performance?

To maintain optimal performance:

• Store at -20°C for long-term storage (up to 1 year from date of receipt)

• Aliquot to avoid repeated freeze-thaw cycles, which can degrade antibody performance

• For short-term use, store small working aliquots at 4°C (up to 1 month)

• The antibody is provided in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps maintain stability

What are the cross-reactivity considerations across different species?

While the antibody was raised against human Factor X sequences, cross-reactivity has been reported:

Researchers working with non-human models should perform validation experiments to confirm reactivity in their specific experimental system .

What are the regulatory and ethical considerations for research applications?

All product information emphasizes that this antibody is strictly for research use only (RUO) . Important considerations include:

• Not for diagnostic use: The antibody has not been validated for diagnostic applications and should not be used for such purposes

• Not for therapeutic applications: The antibody is not suitable for therapeutic interventions

• Laboratory use only: The antibody is intended for in vitro laboratory research only

• Ethical considerations: When designing experiments using this antibody, researchers should follow institutional guidelines for ethical research practices

Understanding these limitations ensures appropriate use of the antibody within the proper regulatory framework.